Dallah Healthcare Company

SASE:4004 Stock Report

Market Cap: ر.س14.8b

Dallah Healthcare Future Growth

Future criteria checks 3/6

Dallah Healthcare is forecast to grow earnings and revenue by 14.9% and 11.9% per annum respectively. EPS is expected to grow by 14.3% per annum. Return on equity is forecast to be 17.2% in 3 years.

Key information

14.9%

Earnings growth rate

14.3%

EPS growth rate

Healthcare earnings growth15.5%
Revenue growth rate11.9%
Future return on equity17.2%
Analyst coverage

Good

Last updated10 Dec 2024

Recent future growth updates

Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 14
Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Recent updates

With EPS Growth And More, Dallah Healthcare (TADAWUL:4004) Makes An Interesting Case

Dec 21
With EPS Growth And More, Dallah Healthcare (TADAWUL:4004) Makes An Interesting Case

Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio

Oct 31
Some Shareholders Feeling Restless Over Dallah Healthcare Company's (TADAWUL:4004) P/E Ratio

The Return Trends At Dallah Healthcare (TADAWUL:4004) Look Promising

Oct 07
The Return Trends At Dallah Healthcare (TADAWUL:4004) Look Promising

Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?

Sep 19
Do Dallah Healthcare's (TADAWUL:4004) Earnings Warrant Your Attention?

Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 14
Dallah Healthcare Company (TADAWUL:4004) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

The Price Is Right For Dallah Healthcare Company (TADAWUL:4004)

Jul 18
The Price Is Right For Dallah Healthcare Company (TADAWUL:4004)

Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist

May 30
Investors Will Want Dallah Healthcare's (TADAWUL:4004) Growth In ROCE To Persist

We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

Apr 16
We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E

Mar 18
What You Can Learn From Dallah Healthcare Company's (TADAWUL:4004) P/E

Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes

Feb 25
Returns On Capital At Dallah Healthcare (TADAWUL:4004) Have Hit The Brakes

Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward

Oct 30
Dallah Healthcare (TADAWUL:4004) Has More To Do To Multiply In Value Going Forward

Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return

Jul 26
Dallah Healthcare (TADAWUL:4004) Is Reinvesting At Lower Rates Of Return

Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)

Apr 17
Returns On Capital Signal Tricky Times Ahead For Dallah Healthcare (TADAWUL:4004)

Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Feb 06
Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends

Dec 05
Dallah Healthcare (TADAWUL:4004) Will Want To Turn Around Its Return Trends

We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

Nov 01
We Ran A Stock Scan For Earnings Growth And Dallah Healthcare (TADAWUL:4004) Passed With Ease

Calculating The Intrinsic Value Of Dallah Healthcare Company (TADAWUL:4004)

Aug 28
Calculating The Intrinsic Value Of Dallah Healthcare Company (TADAWUL:4004)

Dallah Healthcare (TADAWUL:4004) Has Some Way To Go To Become A Multi-Bagger

Aug 12
Dallah Healthcare (TADAWUL:4004) Has Some Way To Go To Become A Multi-Bagger

Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching

Jul 28
Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching

Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%

May 26
Industry Analysts Just Upgraded Their Dallah Healthcare Company (TADAWUL:4004) Revenue Forecasts By 10%

Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)

May 20
Calculating The Fair Value Of Dallah Healthcare Company (TADAWUL:4004)

Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching

Apr 16
Here's Why We Think Dallah Healthcare (TADAWUL:4004) Is Well Worth Watching

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Feb 03
Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Jan 10
Is Now The Time To Put Dallah Healthcare (TADAWUL:4004) On Your Watchlist?

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Oct 19
Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Jul 09
Dallah Healthcare (TADAWUL:4004) Might Be Having Difficulty Using Its Capital Effectively

Forecast: Analysts Think Dallah Healthcare Company's (TADAWUL:4004) Business Prospects Have Improved Drastically

Jun 16
Forecast: Analysts Think Dallah Healthcare Company's (TADAWUL:4004) Business Prospects Have Improved Drastically

Broker Revenue Forecasts For Dallah Healthcare Company (TADAWUL:4004) Are Surging Higher

May 02
Broker Revenue Forecasts For Dallah Healthcare Company (TADAWUL:4004) Are Surging Higher

What Kind Of Shareholders Hold The Majority In Dallah Healthcare Company's (TADAWUL:4004) Shares?

Mar 17
What Kind Of Shareholders Hold The Majority In Dallah Healthcare Company's (TADAWUL:4004) Shares?

Has Dallah Healthcare (TADAWUL:4004) Got What It Takes To Become A Multi-Bagger?

Mar 02
Has Dallah Healthcare (TADAWUL:4004) Got What It Takes To Become A Multi-Bagger?

Dallah Healthcare (TADAWUL:4004) Shareholders Booked A 45% Gain In The Last Year

Feb 15
Dallah Healthcare (TADAWUL:4004) Shareholders Booked A 45% Gain In The Last Year

Should You Buy Dallah Healthcare Company (TADAWUL:4004) For Its Dividend?

Feb 01
Should You Buy Dallah Healthcare Company (TADAWUL:4004) For Its Dividend?

Are Dallah Healthcare's (TADAWUL:4004) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 05
Are Dallah Healthcare's (TADAWUL:4004) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Dallah Healthcare Company's (TADAWUL:4004) Intrinsic Value Is Potentially 26% Below Its Share Price

Dec 22
Dallah Healthcare Company's (TADAWUL:4004) Intrinsic Value Is Potentially 26% Below Its Share Price

Will Dallah Healthcare (TADAWUL:4004) Multiply In Value Going Forward?

Nov 20
Will Dallah Healthcare (TADAWUL:4004) Multiply In Value Going Forward?

Earnings and Revenue Growth Forecasts

SASE:4004 - Analysts future estimates and past financials data (SAR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264,2156354708439
12/31/20253,8435213146859
12/31/20243,3304923136206
9/30/20243,203471358779N/A
6/30/20243,105444326667N/A
3/31/20243,010385415724N/A
12/31/20232,943360329626N/A
9/30/20232,831325348562N/A
6/30/20232,682270369549N/A
3/31/20232,595286333519N/A
12/31/20222,488274267442N/A
9/30/20222,370305214367N/A
6/30/20222,313311122260N/A
3/31/20222,220289166290N/A
12/31/20212,105259246362N/A
9/30/20211,935202178305N/A
6/30/20211,742206240363N/A
3/31/20211,498165110215N/A
12/31/20201,31813254183N/A
9/30/20201,25715082211N/A
6/30/20201,20712335198N/A
3/31/20201,24613133244N/A
12/31/20191,252147106307N/A
9/30/20191,22711088290N/A
6/30/20191,20611543264N/A
3/31/20191,1931195255N/A
12/31/20181,181142-51204N/A
9/30/20181,189172-158184N/A
6/30/20181,203217N/A253N/A
3/31/20181,218268N/A297N/A
12/31/20171,212295N/A353N/A
9/30/20171,202284N/A457N/A
6/30/20171,180268N/A387N/A
3/31/20171,181252N/A382N/A
12/31/20161,163225N/A343N/A
9/30/20161,122228N/A244N/A
6/30/20161,073194N/A261N/A
3/31/20161,030175N/A233N/A
12/31/2015985165N/A214N/A
9/30/2015948161N/A204N/A
6/30/2015917156N/A168N/A
3/31/2015892154N/A151N/A
12/31/2014859147N/A149N/A
9/30/2014831149N/A137N/A
6/30/2014805149N/A138N/A
3/31/2014773138N/A108N/A
12/31/2013750137N/A102N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4004's forecast earnings growth (14.9% per year) is above the savings rate (14.7%).

Earnings vs Market: 4004's earnings (14.9% per year) are forecast to grow faster than the SA market (5.9% per year).

High Growth Earnings: 4004's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4004's revenue (11.9% per year) is forecast to grow faster than the SA market (-0.6% per year).

High Growth Revenue: 4004's revenue (11.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4004's Return on Equity is forecast to be low in 3 years time (17.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 05:09
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dallah Healthcare Company is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ibrahim ElaiwatAljazira Capital Company
Jassim Al-JubranAljazira Capital Company
Rim Ben Salah GharbiAlphaMena